Cardinal Health said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.

Cardinal Health (NYSE:CAH) has provided an update to its guidance for non-GAAP EPS for fiscal year 2025, now expecting its bottom line to be toward the high end of its anticipated range of $7.75 to $7.90 per share. The current consensus EPS estimate for FY ...